Vermont to require drug makers to explain price increases


In this Feb. 4, 2016 file photo, pharmaceutical chief Martin Shkreli speaks on Capitol Hill in Washington during the House Committee on Oversight and Reform Committee hearing on a decision by his former company, Turing Pharmaceuticals, to significantly raise the price of the anti-parasitic medication Daraprim. A bill awaits Vermont Gov. Peter Shumlin's signature in May 2016 that would make it the first state requiring drug companies to explain their price increases.



from Biotech News